Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

AISEC EDGAR SCHEDULE 13GFiled 26 h ago

Surrozen, Inc.: AI Biotechnology LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 20 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

AI Biotechnology LLC amended its Schedule 13G filing on Surrozen, Inc., updating its beneficial ownership stake with the SEC under accession number 0001193125-26-470421. The filing, submitted via Donnelley Financial Solutions, reflects a change to the investor's previously reported position in the clinical-stage biotech. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts relative to the 5% threshold, making the update a signal of shifting institutional interest in Surrozen. The specific revised share count and percentage were not detailed in the filing summary. Investors will watch for further 13G or 13D activity to gauge whether AI Biotechnology's position is being built up or trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Surrozen, Inc., AI Biotechnology LLC